Balparda Kepa, Escobar Giraldo Mariana, Valencia Gómez Yeliana M, Franco Sánchez Isabela, Herrera Chalarca Tatiana
Department of Cornea and Refractive Surgery, Clínica de Oftalmología Sandiego, Medellín, Colombia.
Department of Clinical Research, Black Mammoth Surgical, Medellín, Colombia.
Clin Ophthalmol. 2024 Oct 2;18:2741-2749. doi: 10.2147/OPTH.S472606. eCollection 2024.
To determine clinical and refractive results after the implantation of EyeCryl Phakic Toric intraocular lens in patients with stable keratoconus.
The study included all patients diagnosed with keratoconus who underwent implantation of an EyeCryl Phakic Toric intraocular lens (Biotech Healthcare Holding; Ahmedabad, India) in at least one eye and had a follow-up of at least 12 months. Visual and refractive data were collected for all patients, along with corneal tomography measurements using Pentacam, and vault measurement using optical coherence tomography. This retrospective study was conducted at a high-volume private refractive surgery center in Medellín, Colombia.
A total of 83 eyes from 47 patients were included in the study. The majority (71.1%) were female, with a mean age of 31.2 ± 5.1 years. After 12 months of follow-up post-surgery, the spherical equivalent improved significantly from -8.19 ± 4.04 D to -0.06 ± 0.48 D (p < 0.001). Furthermore, 77% of eyes had a post-surgical spherical equivalent within ±0.50 D, while 92% had residual astigmatism ≤0.50 D. Twelve months after surgery, mean manifest astigmatism was -0.28 ± 0.27 D. Uncorrected visual acuity also showed improvement, from 1.11 ± 0.35 LogMAR to 0.14 ± 0.11 LogMAR. Moreover, 52.4% of eyes demonstrated an improvement of at least one line in best-corrected visual acuity. Notably, no intraoperative or postoperative complications were observed in the study population.
The implantation of EyeCryl Phakic Toric intraocular lenses represents a highly effective and safe option for correcting refractive errors in patients with a history of keratoconus. Refractive accuracy is excellent, and a significant proportion of patients experienced an improvement in their best-corrected vision by at least one line.
确定在圆锥角膜病情稳定的患者中植入EyeCryl有晶体眼散光人工晶状体后的临床和屈光结果。
该研究纳入了所有被诊断为圆锥角膜且至少一只眼睛植入了EyeCryl有晶体眼散光人工晶状体（印度艾哈迈达巴德的Biotech Healthcare Holding公司生产）并接受了至少12个月随访的患者。收集了所有患者的视力和屈光数据，以及使用Pentacam进行的角膜断层扫描测量和使用光学相干断层扫描进行的前房深度测量。这项回顾性研究在哥伦比亚麦德林一家大型私立屈光手术中心进行。
该研究共纳入了47例患者的83只眼睛。大多数患者（71.1%）为女性，平均年龄为31.2±5.1岁。术后12个月随访时，等效球镜度从-8.19±4.04 D显著改善至-0.06±0.48 D（p<0.001）。此外，77%的眼睛术后等效球镜度在±0.50 D以内，而92%的眼睛残余散光≤0.50 D。术后12个月，平均显性散光为-0.28±0.27 D。未矫正视力也有所改善，从1.11±0.35 LogMAR提高至0.14±0.11 LogMAR。此外，52.4%的眼睛最佳矫正视力至少提高了一行。值得注意的是，在研究人群中未观察到术中或术后并发症。
植入EyeCryl有晶体眼散光人工晶状体是矫正有圆锥角膜病史患者屈光不正的一种高效且安全的选择。屈光准确性极佳，相当一部分患者的最佳矫正视力至少提高了一行。
